Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis

Parkinsonism and Related Disorders

Volumn 19, Issue 3, 2013, Pages 295-299

  Voss, Tiffini ^a   Bahr, Daun ^b   Cummings, Jeffrey ^c   Mills, Roger ^b   Ravina, Bernard ^d   Williams, Hilde ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ACADIA PHARMACEUTICALS INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d BIOGEN   (United States)

Author keywords

Delusions; Hallucinations; Parkinson disease; Psychosis; Rating scales

Indexed keywords

CLOZAPINE; PIMAVANSERIN;

ARTICLE; AUDITORY HALLUCINATION; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); DELUSION; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSON DISEASE PSYCHOSIS; PRIORITY JOURNAL; PSYCHOSIS; RELIABILITY; SCALE FOR ASSESSMENT OF POSITIVE SYMPTOMS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VISUAL HALLUCINATION;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; PSYCHOTIC DISORDERS; SENSITIVITY AND SPECIFICITY;

EID: 84874251238     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.10.022     Document Type: Article

References (15)

1. Factor S.A., Feustel P.J., Friedman J.H., Comella C.L., Goetz C.G., Kurlan R., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003, 60(11):1756-1761.
2. Andreasen NC. The Scale for Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa; 1984.
3. Fernandez H.H., Aarsland D., Fenelon G., Friedman J.H., Marsh L., Troster A.I., et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Movement Disorders 2008, 23(4):484-500.
4. Voss T.S., Brocht A.F., Ravina B. Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis. Movement Disorders 2010, 25(1):124-125.
5. Bahr D., Johnson A., Williams H., Mills R. An exploratory analysis of the factor structure of the Scale for the Assessment of Positive Symptoms (SAPS) in Parkinson's disease patients with psychosis. Movement Disorders 2009, 24(S1):S434.
6. Diederich N.J., Goetz C.G. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 2008, 71(9):677-684.
7. Khan A., Leventhal R.M., Khan S.R., Brown M.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 2002, 22(1):40-45.
8. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moor T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administrations. PLoS Medicine 2008, 5(2):e45.
9. Meltzer H.Y., Mills R., Revell S., Williams H., Johnson A., Bahr D., et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010, 35(4):881-892.
10. Acadia Pharmeceuticals Inc A study of safety and efficacy of pimavanserin (ACP-103) in patients with Parkinson's disease psychosis 2000, [Internet], National Library of Medicine (US), Bethesda (MD), [cited 2012 Aug 22]. Available from:, NLM Identifier: NCT00477672. http://clinicaltrials.gov/show/NCT00477672.
11. Acadia Pharmeceuticals Inc A study of safety and efficacy of pimavanserin (ACP-103) in patients with Parkinson's disease psychosis 2000, [Internet], National Library of Medicine (US), Bethesda (MD), [cited 2012 Aug 22]. Available from:, NLM Identifier: NCT00658567. http://clinicaltrials.gov/show/NCT00658567.
12. The Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The New England Journal of Medicine 1999, 340(10):757-763.
13. Ravina B., Marder K., Fernandez H.H., Friedman J.H., McDonald W., Murphy D., et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders 2007, 22(8):1061-1068.
14. Fenelon G., Mahieux F., Huon R., Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000, 123(4):733-745.
15. Holroyd S., Currie L., Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2001, 70(6):734-738.